Weight LossFDA Approved
Setmelanotide
Also known as: Imcivree · RM-493
An FDA-approved MC4R agonist exclusively for patients with rare genetic obesity mutations (POMC, PCSK1, or LEPR deficiencies).
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~11 hours
Typical Dose
1–3 mg daily
Administration
Subcutaneous injection
Mechanism of Action
Bypasses broken genetic satiety pathways by directly activating MC4R to restore hunger regulation in genetically obese patients.
Key Research Areas
weight lossgenetic obesityMC4RFDA approvedrare disease
Frequently Asked Questions
What is Setmelanotide?▾
An FDA-approved MC4R agonist exclusively for patients with rare genetic obesity mutations (POMC, PCSK1, or LEPR deficiencies).
How does Setmelanotide work?▾
Bypasses broken genetic satiety pathways by directly activating MC4R to restore hunger regulation in genetically obese patients.
What is the recommended dosage for Setmelanotide?▾
The typical research dosage is 1–3 mg daily, administered via Subcutaneous injection. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of Setmelanotide?▾
The half-life of Setmelanotide is approximately ~11 hours. This affects dosing frequency and timing in research protocols.
Is Setmelanotide FDA approved?▾
Yes, Setmelanotide is FDA approved for specific medical indications. Consult your physician for proper medical guidance.
Research Disclaimer
The information provided about Setmelanotide is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.